scholarly journals Acupuncture and Phytotherapy Applications in Non-Alcoholic Fatty Liver

2021 ◽  
Vol 5 (2) ◽  
pp. 01-03
Author(s):  
Hayriye Alp
Keyword(s):  
Liver Enzymes ◽  
High Dose ◽  
Aromatic Plants ◽  
Medicinal And Aromatic Plants ◽  
Alcoholic Fatty Liver ◽  
Elevated Liver Enzymes ◽  
Body Acupuncture ◽  
Treatment Of Obesity ◽  
Primary Support ◽  
Support Treatment

Phytotherapy, medicinal and aromatic plants, algae, fungi and lichens, or their extracts, such as gum, balsam and resin, extracts, essential oils, candles and fixed oils with herbal preparations prepared in various forms (tea, capsule, tablet, syrup, drop , lozenges, sachets, etc.) to be protected from diseases, to treat diseases or to support treatment. Phytotherapy; It is based on scientific research and clinical studies. Historically, it has been the primary support of doctors in the treatment of diseases. Objective:We offer here; In addition to the treatment of obesity with acupuncture and phytotherapeutically artichoke (Cynara scolymus L.) and thistle (Silybum marianum (L.) Gaertn.), dandelion (Taraxacum officinale FH Wigg.) using antidepressants for many years, the treatment of obesity with impaired obesity and elevated liver enzymes. It is a case where a positive decrease is achieved in liver enzymes by giving mix extract. Methods: Yin-tan, Memory, Kid-3, Liv-3, St-36,24,25 in body acupuncture, Shen-men, stomach, larynx, jerome, kidney points were pinned in ear acupuncture. When patients who apply to the outpatient clinic need phytotherapeutic support, liver enzymes are routinely checked. Results:The patient lost both weight and liver enzymes. Conclusions and Recommendations: The biggest disadvantage of these preparations is their uncontrolled and high-dose use. It is most appropriate to give this kind of support treatments by people who are trained and licensed in this regard, especially under the control of a doctor. For this purpose, the Department of Traditional Complementary Medicine provides the development of physicians and pharmacists who have received phytotherapy training.

scholarly journals Potentially hepatotoxic drugs are still being prescribed to liver disease patients under tertiary care: it is time to say enough

2021 ◽  
Vol 5 (4) ◽  
pp. 279-286
Author(s):  
Rodrigo Dorelo ◽  
Samantha T.A. Barcelos ◽  
Magela Barros ◽  
Valeria Elustondo ◽  
Ysela Y.P. Pérez ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Liver Enzymes ◽  
Tertiary Care ◽  
University Hospital ◽  
Decompensated Cirrhosis ◽  
Drug Induced ◽  
Alcoholic Fatty Liver ◽  
Drug Induced Liver Injury ◽  
Elevated Liver Enzymes

Introduction and aim: Drug-induced liver injury (DILI) manifests as a spectrum of clinical presentations that carries morbidity and mortality. Patients with chronic liver disease (CLD), particularly hospitalized, are at high risk for developing DILI. We aimed to investigate the use of potentially hepatotoxic drugs (PHD) in patients with CLD in a tertiary university hospital. Materials and methods: Adult (≥ 18 years-old) with CLD admitted to the hospital from January 2016 to December 2018 were evaluated regarding PHD, assessing the risk of DILI and liver enzymes behavior after exposure. Results: From 931 hospitalized patients with CLD, 291 (31.3%) were exposed to hepatotoxic drugs during their hospitalization. Of those, 244 (83.8%) were cirrhotic. The most frequent causes of liver disease were hepatitis C (41.2%), followed by alcohol (13.2%), hepatitis C/alcohol (11.7%) and non-alcoholic fatty liver disease (5.8%). Decompensated cirrhosis (46.7%) was the main reason for hospital admission. The most often prescribed PHD were antibiotics (67.7%), cardiovascular drugs (34.4%), neuromodulators (26.1%) and anesthetics (19.9%). After exposure, 113 patients (38.8%) presented significant elevated liver enzymes. Surprisingly, PHD were more often prescribed in GI/Liver unit (48.8%) followed by emergency/intensive care unit (28.5%). A total of 65 patients (22%) died, however in neither case was it possible to safely infer causal relationship among PHD, liver enzymes and death. Conclusion: PHD prescription is frequent in patients with CLD even in a tertiary university hospital and in the gastroenterology and hepatology department, exposing these patients to an additional risk.

Effects of high-dose dexamethasone in postpartum women with class 1 haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

2018 ◽  
Vol 39 (3) ◽  
pp. 335-339 ◽  
Author(s):  
Akimasa Takahashi ◽  
Nobuyuki Kita ◽  
Yuji Tanaka ◽  
Shunichiro Tsuji ◽  
Tetsuo One ◽  
...  
Keyword(s):  
Hellp Syndrome ◽  
Liver Enzymes ◽  
Postpartum Women ◽  
High Dose ◽  
High Dose Dexamethasone ◽  
Elevated Liver Enzymes ◽  
Class 1

scholarly journals POTALA KATUROHINYADI KWATHA IN KAPHAJA YAKRIT DALLUDARA (NON-ALCOHOLIC FATTY LIVER DISEASE): A CASE STUDY

2020 ◽  
pp. 62-66
Author(s):  
Ashok Kumar Panda ◽  
Jayram Hazra
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Enzymes ◽  
Large Population ◽  
Alcoholic Fatty Liver ◽  
Elevated Liver Enzymes ◽  
Haematological Profile ◽  
One Year ◽  
Alcoholic Fatty Liver Disease

Non- alcoholic fatty liver disease (NAFLD) is also otherwise termed as Hepatic steatosis and Kaphaja yakrit dalludara in Ayurveda. 34 years male patient, highly educated from a high socio-economic group of Non vegetarian diet habit came to hospital with complain of anorexia, indigestion and distention for three months. The clinical findings revealed that he is slightly obese, hyperglycaemia and dyslipidimia along elevated liver enzymes with fatty liver in USG and Fibro scan. The case was treated with Patolakaturohinyadi Kwatham (PKK) in the dose was 30ml Kasaya with equal quantity of luke warm water twice daily in empty stomach preferable morning and evening for six months. This study proved that PKK can significantly reduced blood sugar, serum Lipids and liver enzymes within three months along with reduction weight and BMI, but change in liver architecture required six months in this therapy. The BARD score and NAFLD score changed to normal after six months of therapy. The patient was kept in observation for further one year without medication and advised to practice yoga, exercise and low carbohydrate and fat diet to study the recurrence of disease. The liver architecture as well as biochemical profile of liver is maintained after one year also. PKK may correct the metabolic dysfunction by increase Agni, digest Ama which helped in the correction of hyperglycaemia and dyslipidaemia. PKK is safe in for six months of use in recommended dose (30ml BID) as there was no adverse sign and symptom observed and no change in biochemical and Haematological profile of Patients.PKK is safe and effective in this case of Kaphaja Yakrit dalludara (NAFLD). It can study further in large population to generated evidence for its efficacy and efficacy in larger group.

scholarly journals Increased liver echogenicity and liver enzymes are associated with extreme obesity, adolescent age and male gender: analysis from the German/Austrian/Swiss obesity registry APV

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Susanne Greber-Platzer ◽  
◽  
Alexandra Thajer ◽  
Svenja Bohn ◽  
Annette Brunert ◽  
...  
Keyword(s):  
Liver Disease ◽  
Arterial Hypertension ◽  
Liver Enzymes ◽  
Male Gender ◽  
Extreme Obesity ◽  
Alcoholic Fatty Liver ◽  
Logistic Regression Models ◽  
Male Adolescents ◽  
Elevated Liver Enzymes ◽  
Multi Center Study

Abstract Background Childhood obesity is often associated with non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease in pediatrics. Methods This multi-center study analyzed liver echogenicity and liver enzymes in relation to obesity, age, gender and comorbidities. Data were collected using a standardized documentation software (APV) from 1.033 pediatric patients (age: 4–18 years, body mass index = BMI: 28–36 kg/m2, 50% boys) with overweight (BMI >90th percentile), obesity (BMI >97th percentile) or extreme obesity (BMI > 99.5th percentile) and obesity related comorbidities, especially NAFLD from 26 centers of Germany, Austria and Switzerland. Liver enzymes aspartate aminotransferase (AST), alanine-aminotransferase (ALT) and gamma glutamyltransferase (gammaGT) were evaluated using 2 cut-off values a) > 25 U/L and b) > 50 U/L. Multiple logistic regression models were used for statistical analysis. Results In total, 44% of the patients showed increased liver echogenicity. Liver enzymes > 25 U/L were present in 64% and > 50 U/L in 17%. Increased liver echogenicity was associated with elevated liver enzymes (> 25 U/L: odds ratio (OR) = 1.4, 95% CI: 1.1–1.9, P < 0.02; > 50 U/L: OR = 3.5, 95% CI: 2.4–5.1, P < 0.0001). Extreme obesity, adolescence and male gender were associated with increased liver echogenicity (extreme obesity vs overweight OR = 3.5, 95% CI: 1.9–6.1, P < 0.0001; age > 14 years vs age < 9 years OR = 2.2, 95% CI: 1.4–3.5, P < 0.001; boys vs girls OR = 1.6, 95% CI: 1.2–2.0, P < 0.001) and elevated liver enzymes (extreme obesity vs overweight > 25 U/L: OR = 4.1, 95% CI: 2.4–6.9, P < 0.0001; > 50 U/L: OR = 18.5, 95% CI: 2.5–135, P < 0.0001; age > 14 years vs age < 9 years > 50 U/L: OR = 1.9, 95% CI: 1.0–3.7, P > 0.05; boys vs girls > 25 U/L: OR = 3.1, 95% CI: 2.4–4.1, P < 0.0001; > 50 U/L: OR = 2.1, 95% CI: 1.5–2.9, P < 0.0001). Impaired glucose metabolism showed a significant correlation with elevated liver enzymes > 50 U/L (OR = 4.4, 95% CI: 1.6–11.8, P < 0.005). Arterial hypertension seemed to occur in patients with elevated liver enzymes > 25 U/L (OR 1.6, 95% CI: 1.2–2.0, P < 0.005). Conclusions NAFLD is strongly related to extreme obesity in male adolescents. Moreover impaired glucose tolerance was observed in patients with elevated liver enzymes > 50 U/L, but arterial hypertension was only present in patients with moderately elevated liver enzymes > 25 U/L.

Sign in / Sign up

Export Citation Format

Share Document